2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2006 2004 2003 2001 2000


1999 1998  1997 1996 1995 1994 1993 1992 1991 1990 1989 1988 1987 1983



70. Märkl F, Huynh D, Endres S, Kobold S.
Utilizing chemokines in cancer immunotherapy.
Trends in Cancer 2022; in press.
JIF 14.2
69. Dorman K, Heinemann V, Kobold S, von Bergwelt-Baildon M, Böck S.
Novel systemic treatment approaches for metastatic pancreatic cancer.
Expert Opinion On Investigational Drugs 2022; 31:249-262.
JIF 6.2
69. Stock S, Kluever AK, Endres S, Kobold S.
Enhanced chimeric antigen receptor T cell therapy through co-application of synergistic combination partners.
Biomedicines 2022; 10:307.
JIF 6.1



68. Umut Ö, Gottschlich A, Endres S, Kobold S.
CAR T cell therapy in solid tumors: a short review.
Magazine of European Medical Oncology 2021; 14:143-149.
JIF 1.0
67. Dezfouli A, Yazdi M, Pockley A, Khosravi M, Kobold S, Wagner E, Multhoff G.
NK cells armed with chimeric antigen receptors (CAR): roadblocks to successful development.
Cells 2021; 10:3390.
JIF 6.7 
67.  Briukhovetska D, Doerr J, Endres S, Libby P, Dinarello Ch, Kobold S.
Interleukins in cancer: from biology to therapy.
Nature Reviews Cancer 2021; 3. Juni 2021
JIF 53.0
66. Schwerdtfeger M, Desiderio V, Kobold S, Regad T, Zappavigna S, Caraglia M.
Long non-coding RNAs in cancer stem cells.
Translational Oncology 2021; 16:218-233.
JIF 4.1
66. Schwerdtfeger M, Benmebarek MR, Endres S, Subklewe M, Desiderio V, Kobold S.
Chimeric antigen receptor–modified T cells and T cell–engaging bispecific antibodies: different tools for the same job.
Current Hematologic Malignancy Reports 2021
JIF 2.5
65. Kobold S.
An in sitro assay to predict primary resistance to PD-1 blockade.
Trends in molecular medicine 2021; 27:297-298.
JIF 11.1


65. Gottschlich A, Endres S, Kobold S.
Therapeutic strategies for targeting IL-1 in cancer.
Cancers 2021; 13:477.
64. Patton E, Mueller K, Adams D,  Anandasabapathy N, Aplin A, Bertolotto C, Bosenberg M, Ceol C, Chi P, Herlyn M, Holmen S, Karreth F, Kaufman Ch, Khan S, Kobold S, Leucci E, Levy C, Lombard D, Lund A, Marie K, Marine JCh, Marais R, McMahon M, Robles- Espinoza CD, Ronai Z, Samuels Y, Soengas M, Villanueva J, Weeraratna A, White R, Yeh I, Zhu J, Zon L, Hurlbert M, Merlino G.
Melanoma models for the next generation of therapies.
Cancer Cell 2021; 39:610-631.
JIF2020 26.6



64. Koenig L, Boehmer D, Metzger P, Schnurr M, Endres S, Rothenfusser S.
Blocking inflammation on the way: rationale for CXCR2 antagonists for the treatment of COVID-19.
Journal of Experimental Medicine 2020; 217:e20201342.

JIF 10.9


63. Kruger S, Cadilha Bvon Bergwelt-Baildon M, Endres S, Kobold S.
Challenges in clinical trial design for T cell-based cancer immunotherapy.
Clinical Pharmacology & Therapeutics 2020; 107:47-49.

JIF 8.7




62. Lesch S, Benmebarek MR, Cadilha B, Stoiber S, Subklewe M, Endres S, Kobold S.
Determinants of response and resistance to CAR T cell therapy.
Seminars in Cancer Biology 2019
JIF 9.7


61. Pinto C, Bergmann M, Briukhovetska D, Nuessler V, Sznol M, von Bergwelt-Baildon M, Kobold S.
6th Immunotherapy of cancer conference (ITOC): advances and perspectives, a meeting report.
Journal for ImmunoTherapy of Cancer 2019
JIF 8.7


61. Orth M, Metzger P, Gerum SMayerle J, Schneider G, Belka C, Schnurr M, Lauber K.
Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches.
Radiation Oncology 2019; 14:141.
JIF 2.9


61. Kruger S, Ilmer M, Kobold S, Cadilha B, Endres S, Ormanns S, Schuebbe G, Renz W, D´Haese J, Schloesser H, Heinemann V, Subklewe M, Boeck S, Werner J, von Bergwelt-Baildon M.
Advances in cancer immunotherapy 2019 – latest trends.
Journal of Experimental and Clinical Research  2019; 38:268.
JIF 6.2


60. Stoiber S, Cadilha B, Benmebarek MR, Lesch S, Endres S, Kobold S.
Limitations in the design of chimeric antigen receptors for cancer therapy.
Cells 2019; 8:E472:1-26
JIF 7.6


59. Darowski D, Kobold S, Jost C, Klein C.
Combining the best of two worlds: Highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells.
Monoclonal Antibodies 2019; 20:1-11
JIF 5.2
59. Benmebarek MR, Karches C, Cadilha B, Lesch S, Endres S, Kobold S*.
Killing mechanisms of chimeric antigen receptor (CAR) T cells.
International Journal of Molecular Sciences 2019; 20(6)
JIF 3.7


58. Kobold S.
Innate and adaptive immunity combined for cancer treatment. (comment)
Proceedings of the National Academy of Sciences USA 2019, 116:1087-1088
JIF 9.5


58. Tokarew NOgonek JEndres S, von Bergwelt-Baildon M, Kobold S.
Teaching an old dog new tricks: next generation CAR T cells.
British Journal of Cancer 2019; 120:26-37
JIF 6.2


57. Duewell P, Endres S, Kobold S.
Innate immune stimulation in cancer therapy.
Hematology/Oncology Clinics of North America 2018
JIF 3.1


56. Zhang J, Endres S, Kobold S.
Enhancing T cell infiltration to enable cancer immunotherapy.
Immunotherapy 2018
JIF 3.5






55. Kobold S, Pantelyushin S, Rataj F, vom Berg J.
Rationale for combining bispecific T cell activating antibodies with checkpoint blockade for cancer therapy.
Frontiers Oncology 2018; 9:1955
JIF 2.0


55. Kobold S, Krackhardt A, Schlösser H, Wolf D.
Immuno-Oncology: A Brief Overview
Deutsche Medizinische Wochenschrift 2018, 143:1006-1013.
JIF 0.6


54. Markota A, Endres S, Kobold S.
Targeting interleukin-22 for cancer therapy.
Human Vaccines & Immunotherapeutics 2018; 14:2012-2015
JIF 2.2


53. Rataj F, Endres S, Kobold S.
When the inhibitor is turned into stimulator: novel aspects in T cell engineering.
Translational Cancer Research 2018
JIF 1.8


52. Gottschlich A, Endres S, Kobold S.
Can we use interleukin-1ß blockade for lung cancer treatment?
Translational Lung Cancer Research 2018; 7:160-164
JIF 1.8







51. Kobold S.
Komplexe Biosimilars in der Onkologie. Rituximab, Trastuzumab & co.
TZM News 2017; Ausgabe 4

51. Cadilha B, Dorman K, Rataj F, Endres S, Kobold S.
Enabling T cell recruitment to tumors as a strategy for improving adoptive T cell therapy.
European Oncology and Haematology 2017; 13:66-73.









50. Bauer C, Kuehnemuth B, Duewell P, Ormanns S, Gress T, Schnurr M.
revailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer.
Cancer Letters 2016
JIF 6,0


50. Kobold S, Endres S.
Prinzipien der Immunotherapie von Tumoren.
TZM News 1 / 2016 (18 Jg.)







49. Kobold S, Duewell P, Schnurr M, Subklewe M, Rothenfusser S, Endres S.
Immunotherapie von Tumoren. Aktivierte T-Zellen als gemeinsame Endstrecke neu zugelassener Therapien.
Deutsches Ärzteblatt International 2015; 112:809-15
JIF 3,6

Immunotherapy in tumors. Activated T cells as a new treatment modality.
Deutsches Ärzteblatt International 2015; 112:809-15
JIF 3,6


48. Schnurr M, Düwell P, Bauer C, Rothenfusser S, Lauber K, Endres S, Kobold S.
Strategies to relieve immunosuppression in pancreatic cancer.
Immunotherapy 2015; 7:363-76
JIF 2,4







47. Suttorp NEndres S. Therapy and prevention of infectious diseases Drug Research 2014; 64 Suppl 1:S1. 

46. Kobold S, Wiedemann G, Rothenfusser S, Endres S.
Modes of action of TLR7 agonists in cancer therapy.
Immunotherapy 2014; 6:1085-95
JIF 2.4







45. Lichtenegger FS, Schnorfeil FM, Hiddemann W, Subklewe M.
Current strategies in immunotherapy for acute myeloid leukemia.
Immunotherapy 2013; 5, 63–78.







44. Endres S, Meuer S, Scriba PC.
Klinische Immunintervention: aktuelle und künftige Ansätze
Arzneimittelforschung 2012; Volume 62.


43. Hotz C, Bourquin C.
Systemic cancer immunotherapy with Toll-like receptor 7 agonists: Timing is everything.
Oncoimmunology 2012; 1:227-228.


43.  Merk M, Mitchell R, Endres S, Bucala R.
D-Dopachrome tautomerase (D-DT or MIF-2): Doubling the MIF cytokine family.
Cytokine 2012; 59:10-7.







42.  Schmidt A, Endres S, Rothenfusser S.
Viral nucleic acid pattern recognition by RIG-I-like helicases.
Journal of Molecular Medicine 2010; 89:5-12







41.   Bourquin C, Voelkl A, Endres S.
Toll-like receptor-7 ligands for the tumor therapy.
Arzneimittel-Forschung Drug Research 2006; 16


40.  Endres S, Schreiber S, Beck S, Hartmann G, Bourquin C.
Toll-like receptor-9 ligands in tumor models.
Arzneimittel-Forschung Drug Research 2006; 14-15







39.   Lungstras-Bufler K, Bufler P,Abdullah R, Rutherford C, Endres S, Abraham E, Dinarello C, Rodriguez R.
High cytokine levels at admission are associated with fatal outcome in patients with necrotizing fasciitis.
European Cytokine Network 2004; 15:135-38







38.   Dugas M, Weinzierl S, Pecar A, Endres S, Hasford J.
Design and implementation of a common drug information database for a university hospital.
Pharmacy World Science 2003; 25:156-161


37.   Endres S, Hartmann G.
Therapeutische Oligonukleotide.
Deutsches Ärzteblatt 2003; 47:2577-82


36.  Rothenfusser S, Tuma E, Wagner M, Endres S, Hartmann G.
Recent advances in immunostimulatory CpG-oligonucleotides.
Current Opinions in Microbiology 2003; 5


35.  Eigler A, Eigenbrod S, Endres S.
Medikamentös induzierte Pankreatitis.
Deutsche Medizinische Wochenschrift 2003; 128:1-4


34.   Lorenz R, Endres S.
Diagnosis and treatment of acute hepatitis C.
UpToDate (on-line textbook) 2003;







33.   Rothenfusser S, Tuma E, Endres S, Hartmann G.
Plamacytoid dendritic cells: The key to CpG.
Human Immunology 2002; 63:1111-9


32.  Schnurr M, Galambos P, Scholz C, Dauer M, Krug A, Hartmann G, Eigler A, Endres S.
Dendritische Zellen - Träger tumorgerichteter Immuntherapie.
Deutsches Ärzteblatt 2002; 37:2408-16







31.  Endres S, Buchardi C, Angstwurm M.
Diagnosespektrum in einer internistischen Notaufnahme.
Der Internist 2001; 42:1462-4


30.   Kirchgeorg M, Endres S.
Patienten suchen und finden Gesundheitsinformationen im Internet.
Hessisches Ärzteblatt 2001; 9:437-41


29.   Eigler A, Loher F, Endres S.
Suppression der Synthese des Tumornekrosefaktors.
Der Internist 2001; 1:28-34


28.  Rothenfußer S, Jahrsdörfer B, Krug A, Endres S, Hartmann G. 
CpG-Oligonukleotide: Therapie mit bakterieller DNA.
Deutsches Ärzteblatt 2001; 15:981-5







27.  Endres S, Siegmund B, Hartmann G, Eigler A.
Pharmakologische Suppression der Synthese von Tumor-Nekrose-Faktor.
Arzneimittel Forschung Drug Research 2000; 50:189-225







26.   Schulze J, Endres S.
Genotyp, Phänotyp und unerwünschte Arzneimittelreaktionen.
Arzneimitteltherapie 1999; 17:196-200


25.  Endres S, Lorenz R, Loeschke K.
Lipid treatment of inflammatory bowel disease.
Current Opinion in Clinical Nutrition 1999; 2:117-20







24.  Hartmann G, Eigler A, Hacker UT, Endres S.
Antisense-Oligonukleotide: Nukleinsäuren zur gezielten Synthesehemmung krankheitsfördernder Proteine.
Deutsches Ärzteblatt 1998; 95:1524-30







23.   Hartmann G, Bidlingmaier M, Eigler A, Hacker UT, Endres S.
Cytokines as targets for therapeutic oligonucleotides.
Cytokines, Cellular and Molecular Therapy 1997; 3:247-56


22.   Folwaczny C, Endres S..
Fischöl zur Rezidivprophylaxe bei M. Crohn?.
Zeitschrift für Gastroenterologie 1997; 35:651-3


21.   Eigler A, Endres S.
Therapie mit Anti-TNF-αntikörper bei Patienten mit Morbus Crohn.
Zeitschrift für Gastroenterologie 1997; 35:899-901


20.   Endres S, Eigler A.
Hemmung der NO-Synthase im septischen Schock.
Der Internist 1997; 38:466-9


19.   Hartmann G, Krug A, Bidlingmaier M, Eigler A, Endres S.
Antisense strategies for inhibition of tumor necrosis factor-a synthesis.
Nucleosides and Nucleotides 1997; 629-34


18.  Eigler A, Sinha B, Hartmann G, Endres S.
Taming TNF: Anti-tumor necrosis factor strategies.
Immunology Today 1997; 18:487-92







17.   Drenth JPH, Endres S, Belohradsky BH, van der Meer JWM. 
Das Hyper-IgD-Syndrom.
Deutsche Medizinische Wochenschrift 1996; 121:1299-1300


16.  Endres S, von Schacky C.
Polyunsaturated fatty acids and human cytokine production.
Current Opinion in Lipidology 1996; 7:48-52







15.  Endres S, Sinha B, Eisenhut T.
n-3 Polyunsaturated fatty acids in the regulation of human cytokine synthesis.
Biochemical Society Transactions 1995; 23:277-81


14.  Endres S, Sinha B, Eigler A.
Tumor-Nekrose-Faktor: Therapeutische Strategien zu Synthesehemmung und Antagonismus.
Deutsches Ärzteblatt 1995; 92:2185-8


13.  Endres S, De Caterina R, Kristensen SD, Schmidt EB.
n-3 Polyunsaturated fatty acids: Update 1995.
European Journal of Clinical Investigation 1995; 25:629-38







12.   De Caterina R, Endres S, Kristensen SD, Schmidt EB.
n-3 Fatty acids and renal diseases.
American Journal of Kidney Diseases 1994; 24:397-415







11. Endres S.
Messengers and mediators: the interaction between lipids, eicosanoids and cytokines.
The American Journal of Clinical Nutrition 1993; 57:789-800


10.   Markewitz A, Faist E, Weinhold C, Lang S, Endres S, Hültner L, Reichart B. 
Alterations of cell-mediated immune response following cardiac surgery.
European Journal of Cardio-thoracic Surgery 1993; 105:15-24


9.   Kristensen SD, De Caterina R, Schmidt EB, Endres S
Fish oil and ischaemic heart disease.
British Heart Journal 1993; 70:212-4







8. Endres S, Gröttrup E.
Deutsches Ärzteblatt 1992; 89:1952-7







7.   Fülle HJ, Endres S, Sinha B, Stoll D, Weber PC, Gerzer R.
Effects of SIN-1 on cytokine synthesis in human mononuclear cells.
Journal of Cardiovascular Pharmacology 1991; 17:113-16







6.   Dinarello CA, Endres S, Meydani SN, Meydani M, Hellerstein MK. 
Interleukin-1, anorexia and dietary fatty acids.
Annals of the New York Academy of Sciences 1990; 587:332-8







5.  Endres S, Hohnloser J.
Therapeutischer Einsatz von Zytokinen.
Münchner Medizinische Wochenschrift 1989; 131:507-9


4.  Endres S, van der Meer JWM, Dinarello CA.
Zytokine in der Pathogenese des Fiebers.
Der Internist 1989; 30:358-61







3.   Dinarello CA, Endres S. A role of interleukin-1 in the pathogenesis of hypersensitivity diseases.
Journal of Cellular Biochemistry 1988; 39:229-38







2.  Endres S, van der Meer JWM, Dinarello CA.
Interleukin-1 in the pathogenesis of fever.
European Journal of Clinical Investigation 1987; 17:469-74







1.  Endres S.
Praktikum der Inneren Medizin in den USA.
Deutsche Medizinische Wochenschrift 1983; 108:1530-3